• All Categories
  • Infectious Diseases
  • Rare Diseases
  • Dermatology
  • Oncology
  • Respiratory
  • Pain
  • Neurology
  • Cardiovascular
  • Women's Health
  • News
article-item
FLYPHARMA VIENNA 2024

Www.flypharmaeurope.com

21 May 2024
article-item
Contents

Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!

21 May 2024
article-item
Comment

Welcome to the spring 2024 issue of Pharmafile! As the weather starts to warm up and spring is finally upon us, the themes of change, growth and rejuvenation are at the forefront of our minds, therefore now seems like the perfect time to consider these themes within the pharma industry.

21 May 2024
article-item
Pharmafile spring 2024

Welcome to the spring 2024 issue of Pharmafile! This issue includes the biggest pharma news, as well as fascinating articles on women's health, rare diseases, and psychoactives!

21 May 2024
article-item
Pharmafocus

Www.pharmafocus.com

21 May 2024
article-item
CHMP grants positive opinion for J&J’s Rybrevant for lung cancer treatment

Janssen, a J&J company, has announced that the CHMP of the EMA has recommended Rybrevant (amivantamab) in combination with chemotherapy.

21 May 2024News
article-item
MHRA approves Ascendis Pharma’s Yorvipath for hypoparathyroidism treatment

Ascendis Pharma has announced that the MHRA has granted marketing authorisation for yorvipath (palopegteriparatide; developed as transcon pth) in GB as a parathyroid hormone (pth) replacement therapy for the treatment of adult patients with chronic hypoparathyroidism.

21 May 2024News
article-item
FDA approves Roche’s Alecensa as lung cancer treatment

Roche has announced that the FDA has approved Alecensa (alectinib) for the adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

21 May 2024News
article-item
FDA approves Pfizer’s Beqvez for haemophilia B treatment

Pfizer has announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate-to-severe haemophilia b.

21 May 2024News
article-item
Eko Health’s AI for heart failure detection approved by FDA

Eko Health has announced that the FDA has approved its low ejection fraction (low EF) detection artificial intelligence (AI).

21 May 2024News
article-item
Regeneron and Mammoth Biosciences to collaborate on CRISPR gene therapies

Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene-editing therapies for multiple tissue and cell types.

21 May 2024News
article-item
FDA to review GSK’s meningococcal vaccine candidate

GSK has announced that the FDA has accepted for review a biologics license application (BLA) for its 5-in-1 meningococcal abcwy (menabcwy) vaccine candidate.

21 May 2024News